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Abstract
The lack of readily available biomarkers is a significant hindrance towards progressing to effective 
therapeutic and preventative strategies for Alzheimer’s disease (AD). Blood-based biomarkers 
have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging 
and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the 
largest source of variability in laboratory testing, there are no currently available standardized 
preanalytical guidelines. The current international working group provides the initial starting point 
for such guidelines for standardized operating procedures (SOPs). It is anticipated that these 
guidelines will be updated as additional research findings become available. The statement 
provides (1) a synopsis of selected preanalytical methods utilized in many international AD cohort 
studies, (2) initial draft guidelines/SOPs for preanalytical methods, and (3) a list of required 
methodological information and protocols to be made available for publications in the field in 
order to foster cross-validation across cohorts and laboratories.
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1. Introduction
There is a large concern regarding the lack of reproducibility of research findings across 
independent laboratories, within laboratory settings, and particularly from academic 
laboratory settings to industry settings [1–4]. In fact, an “unspoken rule” among venture 
capital firms is that 50% of published studies will not replicate in industrial labs [4] and the 
NIH recently outlined a plan to address this problem [2]. While there are a large number of 
factors contributing to this issue, one key factor is the substantial variability in study 
designs, definitions, outcomes, and analytic models that make replication less likely [1]. 
While in the discovery phase of science, it is important to have substantial flexibility; 
however, as scientific discovery proceeds closer to the clinic, there is an increased need for 
optimization and standardization if these discoveries are to replicate reliably and pass 
regulatory authority. Unfortunately, there is oftentimes a disconnect between academic and 
industrial laboratories that hampers movement of important scientific discovery to clinical 
practice, and the generation of standardized methods is one way to bridge this gap. The 
purpose of this whitepaper is the generation of the first set of guidelines for use in research 
of blood-based biomarkers of Alzheimer’s disease (AD).
A major impediment to therapeutic development and clinical trial design for AD is the lack 
of a sensitive, easily-obtained biomarker of disease [8–10]. Biomarkers of disease presence, 
subtypes (i.e., endophenotypes), treatment response, and progression are needed to advance 
therapeutic and preventative opportunities for this rapidly growing health care crisis [8, 11–
13]. Biomarkers are also considered promising tools to enhance all phases of drug discovery 
& development programs by allowing validation of mechanisms of action (MoA) [14]. They 
can be employed in clinical trials to improve diagnostic accuracy in trial participants, thus 
allowing cohorts of patients to be enriched with cases of AD (patient enrichment) [15, 16]. 
In light of this, such markers may not only be useful in patient identification, selection and 
stratification into clinical trials, but may also be useful in the identification of novel 
therapeutic targets.
Over the last two decades, the search for biomarkers that have diagnostic and prognostic 
utility in AD has grown exponentially [9,11] with the majority of work focusing on 
neuroimaging and cerebrospinal (CSF) methodologies [9,11,17]. Advanced neuroimaging 
and CSF techniques yield highly accurate diagnostic accuracy within clinic-based settings 
for detecting AD and blood-based biomarkers represent an approach for enhancing the 
utility of imaging and CSF-based modalities by serving as a generalized screening tool. In 
fact, it has been proposed that blood-based methods can serve as the first step in a multi-step 
diagnostic process [10] as is the case with many other pathologies, such as cardiovascular 
diseases, infectious diseases, and cancer. All screen positives could be referred for 
neuroimaging or CSF assessment for confirmatory purposes (e.g. for diagnostics or 
enrollment into clinical trials).
There has been a significant increase in research efforts examining the potential for blood-
based biomarkers of AD. While the search was largely unsuccessful for decades, recent 
work shows promise. In a seminal study, Ray and colleagues [18] analyzed 120 plasma-
based proteins and developed an algorithm consisting of an 18-biomarker panel that 
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accurately distinguished AD patients from healthy controls with an overall classification 
accuracy of 89% as well as accurately identified 81% of mild cognitive impairment (MCI) 
patients who progressed to AD within a 2 to 6-year follow-up period [18]. This study 
represented the first major support for the notion that an AD biomarker profile could yield 
excellent accuracy; however, enthusiasm waned when the findings did not cross-validate on 
an independent assay platform [19]. Despite this initial setback, other groups have continued 
to identify promising signals in peripheral blood, suggesting that a blood-based AD screen 
may be on the horizon [20–29]. Recently, data from well-characterized international cohorts 
have yielded additional candidate biomarkers and panels [25,30]. In the Texas Alzheimer’s 
Research and Care Consortium (TARCC) cohort a serum-based algorithm yielded a 30-
protein profile with a sensitivity of 88% and specificity of 82% for clinical AD diagnosis 
[31]. The biomarker panel from baseline plasma collected in the Australia Imaging 
Biomarkers and Lifestyle Study of Ageing (AIBL) study consisted of 18 analytes that could 
distinguish AD from healthy controls with a sensitivity of 85% and specificity of 93% [29]. 
A 17-biomarker panel was associated with the diagnosis of MCI and AD in independent 
cohorts from the University of Pennsylvania and Washington University in St. Louis, and 
two of these analytes were found to be highly correlated with the CSF t-tau/Aβ42 ratio[30], 
a strong predictor of future cognitive decline [32,33]. There have been several markers 
consistently altered in AD across cohorts. As outlined by Kiddle and colleagues [34], an 
example of these markers (and number of cohorts they have been replicated across) include: 
apolipoprotein E (5 cohorts), alpha-2-macroglobulin (5 cohorts), complement C3 (5 
cohorts), pancreatic prohormone (5 cohorts), serum amyloid P (4 cohorts), tumor necrosis 
factor (2 cohorts), serum albumin (4 cohorts). Many of these blood-based studies are similar 
in terms of utilizing a common analytical platform; however, the biomarker panels obtained 
are strikingly different, sharing only a few common analytes. For example, in the study by 
Hu and colleagues, several markers were significantly related to dementia status but in the 
opposite direction across cohorts despite the use of the same analytic platform. Additionally, 
several studies have examined the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
proteomic database with different protein signatures reported [29–31]. The discrepant 
findings may be due to the approach employed as the ADNI cohort was utilized as the 
validation sample with the protein signatures being developed in other cohorts (i.e. 
University of Pennsylvania, Washington University, AIBL, TARCC). For comprehensive 
recent reviews of AD proteomic studies conducted across a broad range of cohorts see Lista 
and colleagues [35] and Kiddle and colleagues [34].
Apart from the fact that different initial panels were tested (along with different study 
design), inconsistencies across study findings could be attributable to many preanalytical 
variables, both technical and biological, across studies which may have significant impact 
on the outcomes of the proteomic analyses. There are numerous possible sources of 
preanalytical variations or errors across studies [36]; however out of these, we have 
attempted to highlight only a few important ones. For example, selection of study 
participants in terms of their ethnicity, lifestyle parameters, and statistically sufficient 
numbers could be an important source of variation. In addition, within-subject variation has 
long been highlighted as a possible source of concern as participants need to adhere to 
certain guidelines during the course of the study [37]. Variations could also be introduced by 
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work staff in terms of sample collection mode, collection tubes, preparation, transportation, 
handling, storage and processing as well as different calibration protocols of the equipment 
being used [37,38]. One of the most important factors is the fraction of the blood used for 
testing (serum vs plasma) as not only the abundance of a particular analyte may vary in these 
different fractions, but additives such as heparin, citrate or ethylenediaminetetraacetic acid 
(EDTA) influence the required processing methods and their presence may impact 
biomarker stability and detectability [39–41]. Table 1 presents a list of some of the 
uncontrollable and controllable variables that can impact findings from studies of blood-
based biomarkers in AD. The uncontrollable variables should be reported in the methods of 
protocols and taken into account statistically, whereas the controllable variables represent 
scientific areas where harmonization can occur.
A key step towards generating consistency across studies with regards to blood-based 
biomarkers is the establishment of guidelines for preanalytical protocols [8,42–45] mirroring 
the ongoing initiatives for CSF AD biomarkers [17,46,47]. In fact, such standardization 
efforts for blood-based biomarkers have been underway in other fields for some time 
[24,48–52] and the European Federation of Clinical Chemistry and Laboratory Medicine 
(EFLM, available at http://efcclm.eu/) working group reported a substantial reduction in 
analytic error with improvements in standardization and reliability of instruments, reagents 
and techniques[53]. Notably, the STandards for Alzheimer’s Research in Blood biomarkers 
(STAR-B) was born out of this need and combined with the Blood-Based Biomarker Interest 
Group (BBBIG) to create a Professional Interest Area (PIA) of the Alzheimer’s Association 
International Society to Advance Alzheimer’s Research and Treatment (ISTAART; 
available at https://act.alz.org/site/SPageServer?pagename=ISTAART_homepage). The 
ultimate goal of this international working group is the advancement of blood-based 
biomarkers for the improvement of diagnosis, treatment, and care for those suffering from 
AD. This international collaboration recently has provided an overview regarding the status 
of the field [8] and the Alzheimer’s Association and Alzheimer’s Drug Discovery 
Foundation (ADDF) recently jointly convened a workshop to discuss the state of the field 
[54]. The current work from the working group was undertaken to (1) summarize selected 
methods across many ongoing longitudinal cohorts, (2) take an initial step towards the 
provision of guidelines for preanalytical methods for studies examining the development and 
role of blood-based biomarkers of AD, and (3) provide a minimum set of preanalytical 
variables that must be provided in publications (within the publication or as a supplement) in 
this line of work. Moreover, a set of next-step variables specific to the elderly and dementia 
populations to be examined have been proposed as areas for further research is needed on 
this topic to inform the next revision of the current guidelines.
2. Ongoing Studies
Protocols from 10 (ongoing) Alzheimer’ Disease cohort studies, collaborations as well as the 
National Institute on Aging (NIA) Best Practice Guidelines (also currently being updated) 
were reviewed. These studies were selected as they (1) denote ongoing longitudinal studies 
with specific foci (including blood-based) in biomarkers of AD, (2) represent a significant 
portion of the investigators and/or publications in the topic area, and (3) were willing to 
share detailed protocols regarding blood collection and processing. These studies also 
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presented established protocols for requesting biological samples. Studies/groups that either 
did not respond to the request for protocols or that provided confidential methods were not 
included. The studies included the Alzheimer’s Center Amsterdam [55], Alzheimer’s 
Disease Cooperative Study (ADCS) [56], Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) [57], Australian Imaging, Biomarkers and Lifestyle (AIBL) study [58, 59], 
Dominantly Inherited Alzheimer Network (DIAN) [60–62], Health and Aging Brain among 
Latino Elders (HABLE) [63], King’s Dementia Studies[64], NIA Best Practices[65], Texas 
Alzheimer’s Research and Care Consortium (TARCC) [25,26,31,66], and the Washington 
University Adult Children Study (ACS) [67, 68].
As reported in Table 1, there is significant consistency, but also inconsistency as well as lack 
of technical details across existing studies. The TARCC, ADCS, NIA Best Practices, and 
Alzheimer Center Amsterdam studies do not require fasting blood draws, whereas all others 
make use of them. On the other hand, while “overnight fast” was needed for several studies, 
only the DIAN protocol provided a definition for fasting duration (i.e. 8 hours). Many 
studies provided information regarding needle gauge to be used, though not all, with 21-
gauge being the most commonly utilized size. Tube type varied across studies, with little 
consistency across the category of serum tube selected. Lavender/purple top EDTA plasma 
(K2) was commonly utilized for plasma collection. Centrifugation speed varied across 
studies by speed, duration, temperature and number of spins, with little consistency noted. 
Additionally, the number of revolutions per minute (rpm) in some studies but g-force in 
others was utilized for documentation of centrifugation speed. Sample preparation time 
(total) was most commonly less than or equal to two hours. Samples were most commonly 
stored immediately at −80° C, though some studies utilize immediate freeze on dry ice prior 
to placement in −80° C or liquid nitrogen. The most common long-term storage condition 
was −80° C.
3. Guidelines for Preanalytical Methods
There is a sizable literature documenting the impact of preanalytical methods on proteomic 
results, with most of the errors in laboratory testing coming from outside the analytic phase 
[37] and the majority originating from the preanalytical processing phase [69–72]. 
Specifically, the role of preanalytical variables – affecting the quality of the utilized samples 
and, consequently, the quality of the data produced – is frequently disregarded in clinical 
proteomic analyses [73]. In this regard, it has been suggested that 46% of the errors in 
laboratory testing comes from the preanalytical phase [74].
If any blood-based AD biomarkers are to move from research only (RUO) (discovery phase 
or cross-validation phase) to in vitro diagnostic (IVD) use, standardization of methodologies 
is compulsorily required. While there is still a great need for additional discovery in the area 
of blood-based biomarkers, there is also the necessity to “lock-down” or further clinically 
validate the potential utility of the putative markers currently available, which is the focus of 
the current guidelines. In the United States, all testing on human samples as clinical 
diagnostics must be performed within a regulated good laboratory practice (GLP) setting as 
defined by the Clinical Laboratory Improvement Amendment of 1988 (CLIA ‘88) and other 
associated regulatory guidelines[37]. Many procedures for reaching clinical diagnostic status 
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are determined by standard protocols, standard operating procedures (SOPs) and national or 
international standards, which include the preanalytical procedures provided by the Clinical 
Laboratory Standards Institute (CLSI, available at http://clsi.org/) (formally the National 
Committee for Clinical Laboratory Standards), with strict adherence to such standards being 
important [37].
3.1 Pre-blood draw
There are a number of patient/participant-related factors that will impact blood marker 
results that cannot be accounted for unless proper documentation is obtained. Some 
physiological variables to consider include demographics (age, sex, race/ethnicity), overall 
health, food and beverages consumed prior to collection, chronic drugs/alcohol use, dietary 
supplements, smoking, gestation, diet, exercise, posture or bed rest, as well as patient 
medical conditions and medication status [37,45,48,50,52]. Attempts should be made to 
record information related to these variables as much as possible in order for appropriate 
adjustments to be made during analysis of results [37,48,50]. As can be seen from Table 2, 
the majority of ongoing studies utilize fasting blood-collection though the definition of 
fasting (i.e. 6, 8, 12hr) is not articulated, despite the fact that fasting duration has a known 
impact on many blood-based biomarker levels. Prior work also suggests that some, but not 
all, blood biomarkers exhibit diurnal fluctuations [75–77], which can have a substantial 
impact on the clinical significance of such markers [78]. Standardizing to a morning (before 
10am fasting) blood draw would address the possible diurnal fluctuation issues by 
harmonizing sample collection times across studies.
3.2 Blood collection
There are a number of variables associated with the blood collection procedure itself that 
can impact laboratory assay results. Needle gauge, single- or multi-draw needles, and needle 
composition can impact assay results [37], with hemolysis being a major consideration [79–
82]. For example, in an emergency department setting, use of a 22-gauge needle was 
significantly associated with increased risk of hemolysis [83]. Based on prior results, a 21-
gauge needle is preferred [82,84,85]. Needles can be composed of various materials 
including stainless steel, aluminum, titanium, chromium, iron, manganese, nickel and alloys 
which may impact assays that measure various metals within the blood. A detailed 
description of how to perform a venipuncture is provided by CLSI document H3-A6. There 
are advantages and disadvantages for both serum and plasma, which can fluctuate based on 
the specific marker of interest (e.g. see Rai and Vitzthum [37]).
The site used for blood withdrawal is also an important aspect to consider [86]. The median 
cubital vein, usually easily found and accessed, is considered the preferred site. The 
preparation of the blood collection sites necessitates an accurate cleaning of the skin with 
alcohol (2-propanol) that should be allowed to evaporate, given that the contamination of 
blood with residual alcohol may induce hemolysis, increase the concentrations of some 
analytes therefore producing interferences [87]. In addition, the position of the patient 
(standing, lying, sitting) can have an impact on the hematocrit, and, thus, may cause 
fluctuations in the levels of the analytes [88].
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Moreover, the collection tube can significantly have an affect the obtained results [37,82]. In 
fact, tube components of rubber stoppers, tube wall materials, surfactants, anticoagulants, 
separator gels, clot activators, anticoagulants can all impact assay results [82]. In order to 
comply with Occupational Safety and Health Administration (OSHA, available at https://
www.osha.gov/) guidelines to minimize risks from shattering tubes, plastic tubes have 
replaced glass collection tubes [82,89]. While plastic tubes offer many advantages, such as 
increased gas and water permeability, they also offer several disadvantages such as adhesion 
of proteins to tube walls [82], which has been an issue identified for CSF AD biomarkers 
[90–93]. A detailed review of the impact of tube components on blood-based assay 
performance has been published by Bowen 2010 [82]. The order of tube collection in blood 
draw is also important (CLSI H3-A6 and Rai and Vitzthum [37]) and the current 
recommendations can be found in Figure 1.
3.3 Blood processing
CLSI H18-A4 provides detailed information regarding procedures for handling and 
processing blood specimens for laboratory tests. The time from blood-draw to storage, 
storage temperature, centrifugation parameters, storage volume and container type are all 
important considerations for sample processing [37,44,79,94,95]. A key point for 
consideration is the separation of the sample from the tubes immediately after 
centrifugation. While the processing time may vary by study and the importance by protein 
being measured, one should not store aliquots from serum/plasma that have been in contact 
with cells for more than two hours [79]. Review of Table 1 shows that the majority of 
ongoing protocols require the total processing time to be 2 hours or less, which is preferable. 
See H18-A4 for a detailed list of uncentrifuged specimen stability for a range of times and 
sample types. Per H18-A4, centrifugation parameters that should not be subject to variation 
are: horizontal rotors should be utilized and first centrifugation speed should be at 2000g for 
10 minutes [50]. Parameters that are subject to variation but should be documented include: 
(1) presence and type of separator, (2) temperature of centrifugation, (3) number of 
centrifugations (single or double). With regards to post-centrifugation processing, the 
parameters that should not be subject to variation include: (1) serum/plasma is not to be 
heated or otherwise inactivated, and (2) no storage at −20° C. Parameters subject to variation 
but requiring documentation include: (1) type of secondary container (tube, straw), (2) time 
interval between centrifugation and freezing, (3) sample temperature prior to aliquoting and 
freezing, (4) storage temperature, (5) number of freeze/thaw cycles, and (6) duration of 
storage[50,79]. Polypropylene tips and tubes are recommended to reduce adherence of 
analytes to walls.
3.4 Storage
It has been well acknowledged that protein stability and enzymatic activity are strictly 
dependent on temperature [96]. Long-term storage should be at −80° C or liquid nitrogen. 
According to Rai and colleagues [50], liquid nitrogen storage should represent an excellent 
system to ensure protein stability. However, this way is not often practicable in comparison 
with the availability of −80°C freezers. Hence, the long-term storage temperature should be 
set at −80°C, using freezers whose temperature oscillations are absent or extremely 
diminished. If storage on dry ice is utilized for shipment, the headspace should be vented or 
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the sample should be allowed to sit in −70° C freezer for nine hours prior to thaw to 
facilitate protein stability [97]. Figure 1 provides the proposed guidelines for preanalytical 
processing outlined here.
4. Minimum data required for publication
In order for attempts to be made at cross-validation of biomarker findings across cohorts and 
laboratories, a minimum amount of information is required in addition to utilizing common 
methods. The select preanalytical elements outlined above need to be made available to the 
scientific community within the manuscript or online supplement. Figure 1 not only 
provides the current guidelines, but also a template for provision of key pre-analytic 
elements to be provided within publications for use by other teams.
5. Elderly- and dementia-specific pre-analytic processing variables 
requiring additional research
While the current guidelines provide the first-step in the process towards the generation of 
standards for the field, there remain several topics that require additional research. Most 
importantly relates to the question of how these preanalytical methods require modification 
for geriatric populations. For example, the World Health Organization points out skin 
breakdown as a potential complication of capillary sampling among elderly patients [98]. 
However, a systematic study of the impact of the proposed guidelines specifically among the 
elderly has not been undertaken. In fact, review of the previously published materials 
(including CLSI documents) does not provide information that is age-specific. Therefore, it 
is recommended that the need for specific alterations in the guidelines for the target 
population be undertaken with the current guidelines as a starting framework.
6. Conclusions and future perspectives
In order for blood-based biomarker work in AD to progress, there is a need for adoption of 
guidelines for to standardize preanalytical methods across cohorts and laboratories [8,42]. 
Such guidelines will allow for validation/cross-validation across laboratories and cohorts to 
further validate the clinical performance of putative markers where signals have been 
established. The current guidelines are an attempt to verify such existing putative markers 
for specific clinical utilities and are not intended to stifle in any way new discoveries, which 
are certainly needed in the blood-based AD biomarker arena. The Blood Based Biomarkers 
(PIA) of ISTAART combined the efforts of the STAR-B and BBBIG working groups for a 
single cohesive effort. This working group recently published a position paper on the future 
of blood-based biomarkers of AD in which several needed areas of work were outlined, 
which included the need for guidelines and/or standards for preanalytical methods [8]. The 
current project reflects the continued efforts of that working group and development of the 
first such international guidelines for preanalytical processing of bloods in AD research. It is 
anticipated that these guidelines will be updated as needed based on advancements of the 
field.
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There are multiple potential clinical utilities for blood-based AD biomarkers, and the study 
design must be reflective of that particular purpose. For example, blood-based AD 
biomarkers of disease presence, amyloid positivity, CSF biomarker positive (i.e. diagnostic 
markers) may be developed within clinic settings of case-control designs; however, if such 
markers are to be clinically useful in primary care settings, they must be tested/evaluated 
within such settings as the diagnostic accuracy will vary greatly due to the difference in 
disease base rates and diagnostic practice [99–101]. To date, no such studies have been 
carried out validating putative blood-based AD biomarkers within primary care settings. 
Issues around analytical assay validation, discovery versus clinical diagnostic-grade 
platforms, etc. have also received little attention. As with preanalytical processing variables, 
CLSI guidelines are currently available for assessing performance of assays (e.g. EP5, EP6, 
EP7, EP10, EP14, EP15, EP17, ILA21, ILA23), which should be followed if the assay is to 
move towards clinical application.
To date, there are numerous signals for putative blood-based biomarkers and biomarker 
panels, though no consensus has been reached so far following Institute of Medicine (IOM) 
guidelines [102]. The purpose of the provision of the current guidelines from the 
international working group is to begin the process and dialogue of moving towards 
standardized methods that can be utilized to move putative blood-based biomarkers closer to 
clinical or additional research practices. An important step will be the detailed disclosure of 
the pre-analytic parameters used for collection of clinical samples in publications of the 
clinical evaluation of biomarkers. The current document provides information regarding the 
minimum necessary information regarding these pre-analytic methods utilized to facilitate 
cross-validation of methods across research teams. Additional working group documents 
will address both analytic and post-analytic variables.
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Systematic review: Recent research points towards many promising signals in the search 
for blood-based biomarkers for Alzheimer’s disease. However, there remain 
inconsistencies and failures to replicate in the literature. With the increased emphasis 
from the National Institutes of Health (NIH) on increasing the reproducibility of science, 
there is a great need for guidelines in this line of research, similar to ongoing initiatives 
in neuroimaging and cerebrospinal fluid biomarkers.
Interpretation: There are currently many different protocols for the pre-analytic 
processing of blood samples in Alzheimer’s disease biomarker work. Guidelines were 
generated by this international working group as was a minimum set of information that 
warrants inclusion in research publications.
Future Directions: These guidelines will provide a starting-point for harmonization of 
procedures for the validation phase of blood-based biomarker science in Alzheimer’s 
disease. As new research becomes available, these guidelines will be updated as needed.
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Figure 1. 
Preanalytic Processing Guidelines
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Table 1
Controllable and uncontrollable variables that can impact blood-biomarker findings within Alzheimer’s 
disease studies
Controllable Variables Uncontrollable Variables
Time of collection Demographic characteristics (age, sex, ethnicity/race)
Fasting status ApoE ε4 (and other genes)
Needle size & location of draw Smoking status
Handling of tubes (e.g. inversions) Gestation
Tube type and additives Diet
Tube collection order Medications
Time of sample in collection tube Non-AD comorbidities
Centrifugation parameters Alcohol use
Time from collection to freeze Activity level
Temperature of freeze
Freeze-thaw cycles
Aliquot size
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